2238 Koniaris, Leonidas - Jefferson Medical College - Thomas Jefferson University
Leonidas G. Koniaris , MD, FACS

Leonidas G. Koniaris, MD, FACS

Contact Dr. Koniaris

1901 South Broad Street
Philadelphia, PA 19107

(215) 551-0360
(215) 551-8725 fax

Most Recent Peer-reviewed Publications

  1. Reply to the influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival: An analysis of the Survival, Epidemiology, and End Results database
  2. Influence of Treatment Modality in Outcomes for Different Stages of Resectable Esophageal Adenocarcinomas
  3. Preoperative Imaging for Resectable Periampullary Cancer: Clinicopathologic Implications of Reported Radiographic Findings
  4. Defining Treatment and Outcomes of Hepaticojejunostomy Failure Following Pancreaticoduodenectomy
  5. Does neoadjuvant chemotherapy improve outcomes for patients with gastric cancer?
  6. The thrombophilic state in cancer part II: Cancer outcomes, occult malignancy, and cancer suppression
  7. The influence of Hispanic ethnicity on nonsmall cell lung cancer histology and patient survival: An analysis of the Survival, Epidemiology, and End Results database
  8. Conformational Technique for Non-Anatomic Resection of Liver Lesions
  9. Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia
  10. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma
  11. Is Resection Equivalent to Transplantation for Early Cirrhotic Patients with Hepatocellular Carcinoma? A Meta-Analysis
  12. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
  13. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia
  14. Sarcoid-Reaction Mimicking Metastatic Malignant Hepatopancreatobiliary Tumors: Report of Two Cases and Review of the Literature
  15. Has the survival rate for surgically resected gastric gastrointestinal stromal tumors improved in the tyrosine kinase inhibitor era?
  16. Disclosure of "nonharmful" m 07E4 edical errors and other events: Duty to disclose
  17. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer
  18. Deletion of interleukin-6 improves pyruvate tolerance without altering hepatic insulin signaling in the leptin receptor-deficient mouse
  19. Does surgery or radiation therapy impact survival for patients with extrapulmonary small cell cancers?
  20. A comprehensive analysis of parotid and salivary gland cancer: Worse outcomes for male gender
0